Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease

Benjamin L. Nicholas, Paul Skipp, Sheila Barton, Dave Singh, Dinesh Bagmane, Richard Mould, Gilbert Angco, Jon Ward, Binita Guha-Niyogi, Susan Wilson, Peter Howarth, Donna E. Davies, Stephen Israel Rennard, C. David O'Connor, Ratko Djukanović

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Rationale: Much effort is being made to discover noninvasive biomarkers of chronic airway disease that might enable better management, predict prognosis, and provide new therapeutic targets. Objectives: To undertake a comprehensive, unbiased proteomic analysis of induced sputum and identify novel noninvasive biomarkers for chronic obstructive pulmonary disease (COPD). Methods: Induced sputum was obtained from patients with COPD with a spectrum of disease severity and from control subjects. Two dimensional gel electrophoresis and mass spectrometric identification of differentially expressed proteins were first applied to induced sputum from patients with GOLD stage 2 COPD and healthy smoker control subjects. Initial results thus obtained were validated by a combination of immunoassays (Western blotting and ELISA) applied to a large subject cohort. The biomarkers were localized to bronchial mucosa by immunohistochemistry. Measurements and Main Results: Of 1,325 individual protein spots identified, 37 were quantitatively and 3 qualitatively different between the two groups (P<0.05%). Forty protein spots were subjected to tandem mass spectrometry, which identified 15 separate protein species. Seven of these were further quantified in induced sputum from 97 individuals. Using this sequential approach, two of these potential biomarkers (apolipoprotein A1 and lipocalin-1) were found to be significantly reduced in patients with COPD when compared with healthy smokers. Their levels correlated with FEV1/FVC, indicating their relationship to disease severity. Conclusions: A potential role for apolipoprotein A1 and lipocalin-1 in innate defense has been postulated previously; our discovery of their reduction in COPD indicates a deficient innate defense system in airway disease that could explainincreasedsusceptibility to infectious exacerbations.

Original languageEnglish (US)
Pages (from-to)1049-1060
Number of pages12
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume181
Issue number10
DOIs
StatePublished - May 15 2010

Fingerprint

Lipocalins
Apolipoprotein A-I
Chronic Obstructive Pulmonary Disease
Sputum
Biomarkers
Lipocalin 1
Proteins
Electrophoresis, Gel, Two-Dimensional
Tandem Mass Spectrometry
Immunoassay
Proteomics
Mucous Membrane
Chronic Disease
Western Blotting
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry

Keywords

  • Biomarkers
  • Chronic obstructive pulmonary disease
  • Induced sputum
  • Proteome
  • Two-dimensional polyacrylamide gel electrophoresis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. / Nicholas, Benjamin L.; Skipp, Paul; Barton, Sheila; Singh, Dave; Bagmane, Dinesh; Mould, Richard; Angco, Gilbert; Ward, Jon; Guha-Niyogi, Binita; Wilson, Susan; Howarth, Peter; Davies, Donna E.; Rennard, Stephen Israel; O'Connor, C. David; Djukanović, Ratko.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 181, No. 10, 15.05.2010, p. 1049-1060.

Research output: Contribution to journalArticle

Nicholas, BL, Skipp, P, Barton, S, Singh, D, Bagmane, D, Mould, R, Angco, G, Ward, J, Guha-Niyogi, B, Wilson, S, Howarth, P, Davies, DE, Rennard, SI, O'Connor, CD & Djukanović, R 2010, 'Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease', American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 10, pp. 1049-1060. https://doi.org/10.1164/rccm.200906-0857OC
Nicholas, Benjamin L. ; Skipp, Paul ; Barton, Sheila ; Singh, Dave ; Bagmane, Dinesh ; Mould, Richard ; Angco, Gilbert ; Ward, Jon ; Guha-Niyogi, Binita ; Wilson, Susan ; Howarth, Peter ; Davies, Donna E. ; Rennard, Stephen Israel ; O'Connor, C. David ; Djukanović, Ratko. / Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. In: American Journal of Respiratory and Critical Care Medicine. 2010 ; Vol. 181, No. 10. pp. 1049-1060.
@article{89b34e707395424d8454c0a980cba7a5,
title = "Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease",
abstract = "Rationale: Much effort is being made to discover noninvasive biomarkers of chronic airway disease that might enable better management, predict prognosis, and provide new therapeutic targets. Objectives: To undertake a comprehensive, unbiased proteomic analysis of induced sputum and identify novel noninvasive biomarkers for chronic obstructive pulmonary disease (COPD). Methods: Induced sputum was obtained from patients with COPD with a spectrum of disease severity and from control subjects. Two dimensional gel electrophoresis and mass spectrometric identification of differentially expressed proteins were first applied to induced sputum from patients with GOLD stage 2 COPD and healthy smoker control subjects. Initial results thus obtained were validated by a combination of immunoassays (Western blotting and ELISA) applied to a large subject cohort. The biomarkers were localized to bronchial mucosa by immunohistochemistry. Measurements and Main Results: Of 1,325 individual protein spots identified, 37 were quantitatively and 3 qualitatively different between the two groups (P<0.05{\%}). Forty protein spots were subjected to tandem mass spectrometry, which identified 15 separate protein species. Seven of these were further quantified in induced sputum from 97 individuals. Using this sequential approach, two of these potential biomarkers (apolipoprotein A1 and lipocalin-1) were found to be significantly reduced in patients with COPD when compared with healthy smokers. Their levels correlated with FEV1/FVC, indicating their relationship to disease severity. Conclusions: A potential role for apolipoprotein A1 and lipocalin-1 in innate defense has been postulated previously; our discovery of their reduction in COPD indicates a deficient innate defense system in airway disease that could explainincreasedsusceptibility to infectious exacerbations.",
keywords = "Biomarkers, Chronic obstructive pulmonary disease, Induced sputum, Proteome, Two-dimensional polyacrylamide gel electrophoresis",
author = "Nicholas, {Benjamin L.} and Paul Skipp and Sheila Barton and Dave Singh and Dinesh Bagmane and Richard Mould and Gilbert Angco and Jon Ward and Binita Guha-Niyogi and Susan Wilson and Peter Howarth and Davies, {Donna E.} and Rennard, {Stephen Israel} and O'Connor, {C. David} and Ratko Djukanović",
year = "2010",
month = "5",
day = "15",
doi = "10.1164/rccm.200906-0857OC",
language = "English (US)",
volume = "181",
pages = "1049--1060",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "10",

}

TY - JOUR

T1 - Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease

AU - Nicholas, Benjamin L.

AU - Skipp, Paul

AU - Barton, Sheila

AU - Singh, Dave

AU - Bagmane, Dinesh

AU - Mould, Richard

AU - Angco, Gilbert

AU - Ward, Jon

AU - Guha-Niyogi, Binita

AU - Wilson, Susan

AU - Howarth, Peter

AU - Davies, Donna E.

AU - Rennard, Stephen Israel

AU - O'Connor, C. David

AU - Djukanović, Ratko

PY - 2010/5/15

Y1 - 2010/5/15

N2 - Rationale: Much effort is being made to discover noninvasive biomarkers of chronic airway disease that might enable better management, predict prognosis, and provide new therapeutic targets. Objectives: To undertake a comprehensive, unbiased proteomic analysis of induced sputum and identify novel noninvasive biomarkers for chronic obstructive pulmonary disease (COPD). Methods: Induced sputum was obtained from patients with COPD with a spectrum of disease severity and from control subjects. Two dimensional gel electrophoresis and mass spectrometric identification of differentially expressed proteins were first applied to induced sputum from patients with GOLD stage 2 COPD and healthy smoker control subjects. Initial results thus obtained were validated by a combination of immunoassays (Western blotting and ELISA) applied to a large subject cohort. The biomarkers were localized to bronchial mucosa by immunohistochemistry. Measurements and Main Results: Of 1,325 individual protein spots identified, 37 were quantitatively and 3 qualitatively different between the two groups (P<0.05%). Forty protein spots were subjected to tandem mass spectrometry, which identified 15 separate protein species. Seven of these were further quantified in induced sputum from 97 individuals. Using this sequential approach, two of these potential biomarkers (apolipoprotein A1 and lipocalin-1) were found to be significantly reduced in patients with COPD when compared with healthy smokers. Their levels correlated with FEV1/FVC, indicating their relationship to disease severity. Conclusions: A potential role for apolipoprotein A1 and lipocalin-1 in innate defense has been postulated previously; our discovery of their reduction in COPD indicates a deficient innate defense system in airway disease that could explainincreasedsusceptibility to infectious exacerbations.

AB - Rationale: Much effort is being made to discover noninvasive biomarkers of chronic airway disease that might enable better management, predict prognosis, and provide new therapeutic targets. Objectives: To undertake a comprehensive, unbiased proteomic analysis of induced sputum and identify novel noninvasive biomarkers for chronic obstructive pulmonary disease (COPD). Methods: Induced sputum was obtained from patients with COPD with a spectrum of disease severity and from control subjects. Two dimensional gel electrophoresis and mass spectrometric identification of differentially expressed proteins were first applied to induced sputum from patients with GOLD stage 2 COPD and healthy smoker control subjects. Initial results thus obtained were validated by a combination of immunoassays (Western blotting and ELISA) applied to a large subject cohort. The biomarkers were localized to bronchial mucosa by immunohistochemistry. Measurements and Main Results: Of 1,325 individual protein spots identified, 37 were quantitatively and 3 qualitatively different between the two groups (P<0.05%). Forty protein spots were subjected to tandem mass spectrometry, which identified 15 separate protein species. Seven of these were further quantified in induced sputum from 97 individuals. Using this sequential approach, two of these potential biomarkers (apolipoprotein A1 and lipocalin-1) were found to be significantly reduced in patients with COPD when compared with healthy smokers. Their levels correlated with FEV1/FVC, indicating their relationship to disease severity. Conclusions: A potential role for apolipoprotein A1 and lipocalin-1 in innate defense has been postulated previously; our discovery of their reduction in COPD indicates a deficient innate defense system in airway disease that could explainincreasedsusceptibility to infectious exacerbations.

KW - Biomarkers

KW - Chronic obstructive pulmonary disease

KW - Induced sputum

KW - Proteome

KW - Two-dimensional polyacrylamide gel electrophoresis

UR - http://www.scopus.com/inward/record.url?scp=77953254220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953254220&partnerID=8YFLogxK

U2 - 10.1164/rccm.200906-0857OC

DO - 10.1164/rccm.200906-0857OC

M3 - Article

VL - 181

SP - 1049

EP - 1060

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 10

ER -